



# SINOPHARM GROUP CO. LTD.\*

## 國藥控股股份有限公司

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock code: 01099)

### FORM OF PROXY FOR ANNUAL GENERAL MEETING

Number of shares to which this form of proxy relates <sup>(Note 1)</sup>	
--	--

I/We <sup>(Note 2)</sup> \_\_\_\_\_  
of (address) \_\_\_\_\_  
being the holder(s) of \_\_\_\_\_ domestic shares/H shares <sup>(Note 3)</sup>  
of RMB1.00 each in the share capital of Sinopharm Group Co. Ltd. (the “**Company**”), hereby appoint the Chairman of the meeting or \_\_\_\_\_ <sup>(Note 4)</sup>  
of (address) \_\_\_\_\_  
as my/our proxy(ies) to attend the annual general meeting of the Company to be held at Meeting Room 1813, Sinopharm Plaza, No. 1001 Zhongshan West Road, Changning District, Shanghai, the People's Republic of China (the “**PRC**”) at 9:00 a.m. on Friday, 30 June 2017 (the “**AGM**”) or any adjournment thereof and to vote at such meeting or at any adjournment thereof in respect of the resolutions set out in the notice of AGM dated 12 May 2017 (the “**Notice**”) as hereunder indicated on behalf of me/us, or if no such indication is given, as my/our proxy(ies) thinks fit.

ORDINARY RESOLUTIONS <i>(see Note A)</i>		FOR <sup>(Note 5)</sup>	AGAINST <sup>(Note 5)</sup>
1.	To consider and approve the report of the board of directors of the Company (the “ <b>Board</b> ”) for the year ended 31 December 2016.		
2.	To consider and approve the report of the supervisory committee of the Company (the “ <b>Supervisory Committee</b> ”) for the year ended 31 December 2016.		
3.	To consider and approve the audited financial statements of the Company and its subsidiaries for the year ended 31 December 2016 and the auditors' report.		
4.	To consider and approve the profit distribution plan and payment of the final dividend for the year ended 31 December 2016.		
5.	To consider and approve the appointment of Ernst & Young Hua Ming LLP as the domestic auditor of the Company to hold office until conclusion of the next annual general meeting, and to ratify and confirm its remuneration determined by the audit committee of the Board.		
6.	To consider and approve the appointment of Ernst & Young as the international auditor of the Company to hold office until conclusion of the next annual general meeting, and to ratify and confirm its remuneration determined by the audit committee of the Board.		
7.	To consider and authorize the Board to determine the remuneration of the directors of the Company (the “ <b>Directors</b> ”) for the year ending 31 December 2017.		
8.	To consider and authorize the Supervisory Committee to determine the remuneration of the supervisors of the Company for the year ending 31 December 2017.		

\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”

ORDINARY RESOLUTIONS (see Note A)		FOR (Note 5)	AGAINST (Note 5)
9.	To consider and approve the delegation of the power to the Board to approve the guarantees in favor of third parties with an aggregate total value of not more than 30% of the latest audited total assets of the Company over a period of 12 months; and if the above delegation is not consistent with, collides with or conflicts with the requirements under the Rules Governing the Listing of Securities (the “ <b>Hong Kong Listing Rules</b> ”) on The Stock Exchange of Hong Kong Limited (the “ <b>Hong Kong Stock Exchange</b> ”) or other requirements of the Hong Kong Stock Exchange, the requirements under the Hong Kong Listing Rules or other requirements of the Hong Kong Stock Exchange should be followed.		
SPECIAL RESOLUTION (see Note A)		FOR (Note 5)	AGAINST (Note 5)
10.	To consider and approve to grant a general mandate to the Board to exercise the power of the Company to allot, issue and/or deal with Domestic Shares and/or H Shares (Details of this resolution were contained in the Notice).		

*Note A: Unless otherwise defined herein, the terms used herein shall have the same meanings as defined in the Notice.*

Dated this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_ Signature <sup>(Note 6)</sup> : \_\_\_\_\_

*Notes:*

1. Please insert the number of shares of the Company registered in your name(s) to which this form of proxy relates. If a number is inserted, this form of proxy will be deemed to relate only to those shares. If no number is inserted, the form of proxy will be deemed to relate to all shares registered in your name(s) (whether alone or jointly with others).
2. Please insert the full name(s) (in English or Chinese) and address(es) as registered in the register of members of the Company in block letters.
3. Please insert the number of shares of the Company registered in your name(s) and delete as appropriate.
4. If any proxy other than the Chairman of the meeting of the Company is preferred, please strike out the words “the Chairman of the meeting or” and insert the name and address of the proxy desired in the space provided. A shareholder may appoint one or more proxies to attend and vote on his/her behalf. A proxy need not be a shareholder of the Company. A proxy of a shareholder who has appointed more than one proxy may only vote on a poll. Any alteration made to this form of proxy must be initiated by the person(s) who sign(s) it.
5. Important: If you wish to vote for any resolution, please put a tick in the box marked “**FOR**” or insert the number of shares held by you. If you wish to vote against any resolution, please put a tick in the box marked “**AGAINST**” or insert the number of shares held by you. If you do not indicate how you wish your proxy to vote, your proxy will be entitled to exercise his discretion. Your proxy will also be entitled to vote at his discretion on any resolution properly put to the AGM other than those referred to in the notice of the AGM.
6. This form of proxy must be signed by you or your attorney duly authorised in writing or, in the case of a legal person, must be either executed under its seal or under the hand of its director or other attorney duly authorised to sign the same. In case of joint holders, this form of proxy must be signed by the shareholder whose name stands first in the register of members of the Company.
7. To be valid, for holders of H shares of the Company, this form of proxy and, if such proxy is signed by a person on behalf of the appointer pursuant to a power of attorney or other authority, a notarially certified copy of that power of attorney or other authority must be delivered to the H share registrar of the Company in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 24 hours before the time appointed for holding the AGM. For holders of domestic shares of the Company, this form of proxy and, if such proxy is signed by a person on behalf of the appointer pursuant to a power of attorney or other authority, a notarially certified copy of that power of attorney or other authority must be delivered to the Board Office of the Company in the PRC at Room 1603, Sinopharm Plaza, No. 1001 Zhongshan West Road, Changning District, Shanghai 200051 not less than 24 hours before the time appointed for holding the AGM.
8. In the case of joint holders of shares of the Company, only holder whose name stands first in the register of members of the Company shall alone be entitled to vote at the AGM either in person or by proxy in respect of such shares.
9. The AGM is expected to be held for less than half a day. Shareholders and their proxies who attend the meeting shall arrange for their own transportation and accommodation at their own expenses. Shareholders shall produce their identity documents when attending the AGM.